• ホーム
  • 検索結果
  • Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway.

Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway.

Oncology reports (2014-07-30)
Jin-Hao Miao, Shu-Qiang Wang, Ming-Hui Zhang, Feng-Bin Yu, Lei Zhang, Zhong-Xiang Yu, Yong Kuang
要旨

Galectin-1 (GAL1), a widely expressed β‑galacto-side-binding protein, exerts pleiotropic biological functions. GAL1 has been found to be upregulated in many malignancies; yet the role of GAL1 in the pathophysiology of human osteosarcoma (OS) remains uncertain. The present study was carried out to investigate the expression of GAL1 in human OS tissues and to explore its effects on the growth and invasion of OS cells. OS and corresponding adjacent non-cancerous tissues (ANCT) were collected from 30 consecutive cases. The expression of GAL1 was detected by immunohistochemical assay through tissue microarray procedure. Using small hairpin RNA (shRNA)-mediated GAL1 knockdown (Lv-shGAL1) in OS (MG-63 and U-2 OS) cells, we observed the changes in the malignant phenotype in OS cells in vitro and in vivo. As a consequence, the positive expression of GAL1 was significantly higher in OS tissues than that in the ANCT (63.3 vs. 36.7%, P=0.029), and was positively correlated with distant metastasis in the OS patients (P=0.022). Knockdown of GAL1 suppressed cell proliferative activities and invasive potential and induced apoptosis in OS cells with decreased expression of p38MAPK, p-ERK, Ki-67 and matrix metallopeptidase-9 (MMP-9) and increased expression of caspase-3. In addition, the tumor volume in the MG-63 subcutaneous tumor models treated with Lv-shGAL1 was significantly smaller than that in the negative control (NC) group (P<0.01). Altogether, our findings indicate that high expression of GAL1 is associated with distant metastasis of OS patients, and knockdown of GAL1 inhibits growth and invasion of OS cells possibly through inhibition of the MAPK/ERK pathway, suggesting that GAL1 may represent a potential target for the treatment of cancer.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Anti-p38 MAPK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-MAP Kinase 2 (ERK-2) antibody produced in mouse, clone 1B3B9, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-MAPK14 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-p38 MAPK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-p38 MAPK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-MAPK14 (Ab-182) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-MAPK14 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-MAP Kinase 2 (ERK-2) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution, ~1 mg/mL
Sigma-Aldrich
Anti-p38 MAP Kinase antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution

ソーシャルメディア

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

研究、開発、製造

私たちは、バイオテクノロジーと医薬品の研究&開発および製造のソリューションとサービスを提供する、グローバルなライフサイエンス業界のリーディングサプライヤーです。

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates.All Rights Reserved.

当ウェブサイトのいかなる内容についても、許可なく複写することを禁じます。